We are live on ! Find out more
BCAB icon

BioAtla

36 hedge funds and large institutions have $2.52M invested in BioAtla in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

0.02% less ownership

Funds ownership: 0.45%0.42% (-0.02%)

12% less funds holding

Funds holding: 4136 (-5)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

66% less capital invested

Capital invested by funds: $7.49M → $2.52M (-$4.98M)

Holders
36
Holders Change
-5
Holders Change %
-12.2%
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
9
Reduced
7
Closed
10
Calls
$18K
Puts
Net Calls
+$18K
Net Calls Change
+$11K

BCAB Hedge Fund Activity: Q1 2026 in Review

36 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2026, worth a combined $2.52M — down 66% from $7.49M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of BCAB and 8 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, adding an estimated $467K. The largest seller was Marshall Wace, cutting an estimated $144K.

  • 36 institutional investors held BioAtla (BCAB) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $2.52M of BioAtla stock for Q1 2026, down 66% quarter-over-quarter.
  • 8 funds opened new BioAtla positions in Q1 2026 and 10 closed out, a net change of -2 holders.
  • The largest BioAtla buyer in Q1 2026 was Millennium Management, an estimated $467K added.
  • The largest BioAtla seller in Q1 2026 was Marshall Wace, an estimated $144K sold.

Based on aggregated 13F filings for Q1 2026.